ECSP22018209A - ENHANCED LIPID NANOPARTICLES FOR THE DELIVERY OF NUCLEIC ACIDS - Google Patents

ENHANCED LIPID NANOPARTICLES FOR THE DELIVERY OF NUCLEIC ACIDS

Info

Publication number
ECSP22018209A
ECSP22018209A ECSENADI202218209A ECDI202218209A ECSP22018209A EC SP22018209 A ECSP22018209 A EC SP22018209A EC SENADI202218209 A ECSENADI202218209 A EC SENADI202218209A EC DI202218209 A ECDI202218209 A EC DI202218209A EC SP22018209 A ECSP22018209 A EC SP22018209A
Authority
EC
Ecuador
Prior art keywords
lipid nanoparticles
delivery
nucleic acids
enhanced lipid
enhanced
Prior art date
Application number
ECSENADI202218209A
Other languages
Spanish (es)
Inventor
Christopher Barbosa
Ying Tam
Paulo Lin
Sean Semple
Original Assignee
Acuitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72322523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP22018209(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acuitas Therapeutics Inc filed Critical Acuitas Therapeutics Inc
Publication of ECSP22018209A publication Critical patent/ECSP22018209A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/14—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se proporcionan nanopart?culas lip?dicas que tienen propiedades mejoradas. Tambi?n se describe el uso de nanopart?culas lip?dicas para la administraci?n de un agente terap?utico a primates para el tratamiento de diversas indicaciones.Lipid nanoparticles having improved properties are provided. The use of lipid nanoparticles for the administration of a therapeutic agent to primates for the treatment of various indications is also described.

ECSENADI202218209A 2019-08-14 2022-03-11 ENHANCED LIPID NANOPARTICLES FOR THE DELIVERY OF NUCLEIC ACIDS ECSP22018209A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962886894P 2019-08-14 2019-08-14
PCT/US2020/046407 WO2021030701A1 (en) 2019-08-14 2020-08-14 Improved lipid nanoparticles for delivery of nucleic acids

Publications (1)

Publication Number Publication Date
ECSP22018209A true ECSP22018209A (en) 2022-07-29

Family

ID=72322523

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202218209A ECSP22018209A (en) 2019-08-14 2022-03-11 ENHANCED LIPID NANOPARTICLES FOR THE DELIVERY OF NUCLEIC ACIDS

Country Status (32)

Country Link
US (1) US20230097090A1 (en)
EP (2) EP4013385B1 (en)
JP (2) JP7753190B2 (en)
KR (1) KR20220053599A (en)
CN (1) CN114901253A (en)
AU (2) AU2020328596B2 (en)
BR (1) BR112022002708A2 (en)
CA (1) CA3150458A1 (en)
CL (1) CL2022000351A1 (en)
CO (1) CO2022002685A2 (en)
CR (1) CR20220108A (en)
DE (1) DE112020003843T5 (en)
DK (1) DK4013385T3 (en)
DO (1) DOP2022000038A (en)
EC (1) ECSP22018209A (en)
ES (2) ES2992930T3 (en)
FI (1) FI4013385T3 (en)
GB (1) GB2600859B (en)
GE (2) GEP20257820B (en)
HR (1) HRP20241255T1 (en)
HU (1) HUE068356T2 (en)
IL (1) IL290477A (en)
JO (1) JOP20220037A1 (en)
LT (1) LT4013385T (en)
MX (2) MX2022001720A (en)
PE (1) PE20220968A1 (en)
PH (1) PH12022550363A1 (en)
PL (1) PL4013385T3 (en)
PT (1) PT4013385T (en)
SI (1) SI4013385T1 (en)
UA (1) UA129330C2 (en)
WO (1) WO2021030701A1 (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE067372T2 (en) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipids and lipid nanoparticle formulations for delivery of nucleic acids
CN108368028B (en) 2015-10-28 2021-09-03 爱康泰生治疗公司 Novel lipid and lipid nanoparticle formulations for delivery of nucleic acids
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
JP7355731B2 (en) 2017-08-16 2023-10-03 アクイタス セラピューティクス インコーポレイテッド Lipids for use in lipid nanoparticle formulations
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP3852911B1 (en) 2018-09-21 2025-01-22 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
DK3864163T3 (en) 2018-10-09 2024-05-06 Univ British Columbia COMPOSITIONS AND SYSTEMS COMPRISING TRANSFECTION-COMPETENT VESICLES FREE OF ORGANIC SOLVENTS AND DETERGENTS AND METHODS RELATED THEREOF
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
US12357705B2 (en) 2018-11-09 2025-07-15 Arbutus Biopharma Corporation Negatively charged peg-lipid conjugates
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
CN118490818A (en) 2020-04-22 2024-08-16 生物技术欧洲股份公司 Coronavirus vaccine
KR20230051172A (en) 2020-07-16 2023-04-17 아퀴타스 테라퓨틱스 인크. Cationic Lipids for Use in Lipid Nanoparticles
MX2023001109A (en) 2020-07-27 2023-04-24 Anjarium Biosciences Ag Compositions of dna molecules, methods of making therefor, and methods of use thereof.
CZ310613B6 (en) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoids for the transfection of nucleic acids and their use
MX2023004371A (en) 2020-10-14 2023-07-26 George Mason Res Foundation Inc IONIZABLE LIPIDS, AND METHODS OF MANUFACTURE AND USE THEREOF.
CN117098541A (en) 2020-11-25 2023-11-21 阿卡格拉医药公司 Lipid nanoparticles for delivering nucleic acids and related methods of use
MX2023007574A (en) 2020-12-22 2023-09-29 CureVac SE Rna vaccine against sars-cov-2 variants.
CN113402404B (en) * 2021-04-30 2022-03-11 苏州科锐迈德生物医药科技有限公司 Lipid compound, lipid carrier containing same, nucleic acid lipid nanoparticle composition and pharmaceutical preparation
CN121517316A (en) * 2021-05-06 2026-02-13 阿克丘勒斯治疗公司 Ionizable cationic lipids for RNA delivery
CN115385820B (en) * 2021-05-09 2025-04-29 英维沃生物科技(苏州)有限公司 Cationic lipids and their applications
CA3215963A1 (en) * 2021-05-28 2022-12-01 Yaoxin LIN Lipid compound and use thereof in delivery of nucleic acid
CN113403313B (en) * 2021-06-23 2022-08-19 北京理工大学 sgRNA, plasmid and nano-composite for specifically recognizing human PLK1 locus and application
EP4342929B1 (en) * 2021-06-30 2026-02-04 Jenkem Technology Co. Ltd. (Tianjin) Polyethylene glycol lipid and use thereof
CZ310443B6 (en) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyclohexane lipidoids for nucleic acid transfection and their use
EP4365168B1 (en) 2021-07-23 2025-10-15 Jenkem Technology Co., Ltd. (Tianjin) Polyol-modified lipid compound and preparation method and application thereof
CN115710191B (en) * 2021-08-23 2025-06-10 广州谷森制药有限公司 Cationic lipid compounds
AU2022332372B2 (en) 2021-08-27 2025-12-04 Peking University Constructs and methods for preparing circular rna
EP4763287A2 (en) 2021-09-03 2026-06-24 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
CN115869262A (en) * 2021-09-27 2023-03-31 广州谷森制药有限公司 Novel PEG lipid compound, preparation method, composition and application thereof
AR127312A1 (en) * 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
WO2023061460A1 (en) * 2021-10-15 2023-04-20 厦门赛诺邦格生物科技股份有限公司 Nitrogen-containing cationic lipid and application thereof
EP4422698A1 (en) 2021-10-29 2024-09-04 CureVac SE Improved circular rna for expressing therapeutic proteins
CN118338914A (en) * 2021-11-11 2024-07-12 俄亥俄州创新基金会 Compositions comprising amino lipid compounds and methods of making and using the same
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CN114044741B (en) * 2022-01-13 2022-04-15 北京悦康科创医药科技股份有限公司 Cationic lipid compound, composition containing same and application
WO2023138611A1 (en) * 2022-01-19 2023-07-27 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
CN117243922A (en) 2022-04-29 2023-12-19 北京剂泰医药科技有限公司 lipid nanoparticles
CN115850104B (en) * 2022-04-29 2023-07-18 北京剂泰医药科技有限公司 ionizable lipid compounds
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
CA3248209A1 (en) 2022-05-25 2023-11-30 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
CN117263818B (en) * 2022-06-14 2026-05-08 杭州高田生物医药有限公司 Cationic lipid compounds, their preparation methods and applications
CN114989182B (en) * 2022-06-23 2023-06-23 尧唐(上海)生物科技有限公司 Lipid compounds, compositions comprising them and applications
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN121930111A (en) * 2022-07-19 2026-04-28 深圳深信生物科技有限公司 Amino lipid compound, preparation method and application thereof
WO2024022263A1 (en) * 2022-07-25 2024-02-01 苏州艾博生物科技有限公司 Lipid compound and lipid nanoparticle composition
WO2024031051A1 (en) * 2022-08-05 2024-02-08 Life Technologies Corporation Lipids for nucleic acid delivery
WO2024054843A2 (en) * 2022-09-07 2024-03-14 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CN118265692B (en) * 2022-09-09 2025-06-13 厦门赛诺邦格生物科技股份有限公司 A carbon core cationic lipid
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
CN115417779B (en) * 2022-11-03 2023-06-16 北京华芢生物技术有限公司 Ionizable cationic lipid C6-A1 and nano liposome particles composed of same
CN115417780B (en) * 2022-11-04 2023-06-20 北京华芢生物技术有限公司 Ionizable cationic lipid C5-A2 and nanoliposome particles composed of it
WO2024119098A1 (en) * 2022-12-02 2024-06-06 Prime Medicine, Inc. Lipid nanoparticle (lnp) delivery systems and formulations
CN119095585A (en) * 2022-12-21 2024-12-06 苏州艾博生物科技有限公司 Lipid nanoparticles comprising sterol-modified phospholipids
US20260116844A1 (en) * 2022-12-29 2026-04-30 SurgiNex Co., Ltd. Lipid nanoparticle formulation comprising ionized lipids with branched structure, and use thereof
KR20250153298A (en) 2023-03-08 2025-10-24 큐어백 에스이 Novel lipid nanoparticle formulations for nucleic acid delivery
CN118666726A (en) * 2023-03-17 2024-09-20 尧唐(上海)生物科技有限公司 Lipid compounds for delivering therapeutic agents and preparation methods and applications thereof
EP4704855A1 (en) * 2023-04-26 2026-03-11 Saliogen Therapeutics, Inc. Lipid nanoparticle (lnp) formulations
CN117384055B (en) * 2023-04-27 2024-11-19 仁景(苏州)生物科技有限公司 Ionizable lipids for delivery of therapeutic agents and uses thereof
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
CN119143620A (en) 2023-06-16 2024-12-17 北京剂泰医药科技有限公司 Quick metabolism lipid compounds of (2)
CN116891423B (en) * 2023-07-07 2024-03-01 荣灿生物医药技术(上海)有限公司 Lipid compound, composition, preparation method and application thereof
CN119791061B (en) * 2023-10-11 2026-05-19 中国人民解放军军事科学院军事医学研究院 A method for constructing an animal model of hepatitis A virus infection and its applications
US20250161227A1 (en) 2023-11-17 2025-05-22 Acuitas Therapeutics, Inc. Pegylated lipids
WO2025128696A1 (en) 2023-12-12 2025-06-19 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025132122A1 (en) 2023-12-13 2025-06-26 Berlin Institute Of Health Methods of delivering therapeutics using lipid nanoparticles
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025133105A1 (en) * 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Compositions and methods
WO2025140421A1 (en) * 2023-12-29 2025-07-03 北京剂泰医药科技有限公司 Ionizable lipid compound and use thereof in delivering nucleic acid vaccine
AU2025217182A1 (en) 2024-02-02 2026-08-06 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025174858A1 (en) 2024-02-15 2025-08-21 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
TW202543583A (en) 2024-03-01 2025-11-16 加拿大商阿奎特斯醫療公司 Materials and methods for encapsulating therapeutics in lipid nanoparticles
WO2025186725A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Improved lnp formulations and uses thereof
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
WO2025217264A1 (en) 2024-04-10 2025-10-16 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
CN118319880B (en) * 2024-04-15 2025-02-07 荣灿生物医药技术(上海)有限公司 Lipid nanoparticles, inhalation preparations and applications for efficient delivery of nucleic acids to the lungs
WO2025230906A1 (en) * 2024-04-29 2025-11-06 Saliogen Therapeutics, Inc. Lipid nanoparticle (lnp) formulations
TW202604548A (en) 2024-05-01 2026-02-01 加拿大商阿奎特斯醫療公司 Method of using lipid nanoparticles for intramuscular delivery
WO2025240833A1 (en) 2024-05-17 2025-11-20 Acuitas Therapeutics, Inc. Galnac lipid compounds for use in lipid nanoparticles
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026035680A1 (en) 2024-08-06 2026-02-12 Kernal Biologics, Inc. Compositions and methods for delivery of agents
WO2026072557A2 (en) * 2024-09-24 2026-04-02 Genzyme Corporation Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2026088119A1 (en) 2024-10-24 2026-04-30 Pfizer Inc. Lipidated tlr7/8 modulators as adjuvants and uses thereof
CN119431176B (en) * 2024-11-05 2026-02-13 汉信生物科技(苏州)有限公司 An ionizable cationic lipid, its preparation method and application
WO2026102260A1 (en) 2024-11-08 2026-05-15 Editas Medicine, Inc. Crispr-related methods and compositions targeting angiopoietin like 3 (angptl3)

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
CA2039718C (en) 1989-08-31 2003-02-25 John J. Rossi Chimeric dna-rna catalytic sequences
US6365730B1 (en) 1990-06-19 2002-04-02 Gene Shears Pty. Limited DNA-Armed ribozymes and minizymes
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
AU649074B2 (en) 1990-10-12 1994-05-12 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
DE4216134A1 (en) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog SYNTHETIC CATALYTIC OLIGONUCLEOTIDE STRUCTURES
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
CA2135646A1 (en) 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
JPH07509133A (en) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド Methods and agents for the treatment of animal diseases
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5591317A (en) 1994-02-16 1997-01-07 Pitts, Jr.; M. Michael Electrostatic device for water treatment
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US6197553B1 (en) 1994-07-15 2001-03-06 Merck & Co., Inc. Method for large scale plasmid purification
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5747470A (en) 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US5965542A (en) 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
DE69810781T2 (en) 1997-08-15 2003-09-25 Chisso Corp., Osaka POLYDISPERSE PROPYLENE POLYMER AND METHOD FOR THE PRODUCTION THEREOF
JP2002502831A (en) 1998-02-03 2002-01-29 イネックス ファーマシューティカルズ コーポレイション Systemic delivery of serum-stable plasmid lipid particles for the treatment of cancer
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
US6211140B1 (en) 1999-07-26 2001-04-03 The Procter & Gamble Company Cationic charge boosting systems
EP1412065A2 (en) 2001-07-27 2004-04-28 President And Fellows Of Harvard College Laminar mixing apparatus and methods
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
CA2518475C (en) 2003-03-07 2014-12-23 Alnylam Pharmaceuticals, Inc. Irna agents comprising asymmetrical modifications
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
US6927663B2 (en) 2003-07-23 2005-08-09 Cardiac Pacemakers, Inc. Flyback transformer wire attach method to printed circuit board
CN1882693B (en) 2003-09-15 2012-08-15 普洛体维生物治疗公司 Polyethylene glycol modified lipid compound and its application
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
JP5639338B2 (en) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド Liposome production system and production method
AU2006279906B2 (en) 2005-08-10 2012-05-10 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
EP1986697B1 (en) 2006-02-17 2016-06-29 GE Healthcare Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference
EP2081949B1 (en) 2006-09-22 2014-12-10 GE Healthcare Dharmacon, Inc. Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
WO2008103276A2 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
EP3699172A3 (en) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
KR20220038506A (en) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 Improved lipid formulation
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
ES2613498T3 (en) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. New lipid formulations for the delivery of therapeutic agents to solid tumors
JP5723378B2 (en) 2009-11-03 2015-05-27 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Lipid formulation composition and method for inhibiting transthyretin (TTR)
RU2573409C2 (en) 2009-11-04 2016-01-20 Дзе Юниверсити Оф Бритиш Коламбиа Lipid particles containing nucleic acids and related methods
WO2011066651A1 (en) 2009-12-01 2011-06-09 Protiva Biotherapeutics, Inc. Snalp formulations containing antioxidants
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
US20130017223A1 (en) 2009-12-18 2013-01-17 The University Of British Columbia Methods and compositions for delivery of nucleic acids
EP3391877A1 (en) 2010-04-08 2018-10-24 The Trustees of Princeton University Preparation of lipid nanoparticles
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
WO2011149733A2 (en) 2010-05-24 2011-12-01 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
EP4481047A3 (en) 2010-06-03 2025-04-16 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
EP2449113B8 (en) 2010-07-30 2015-11-25 CureVac AG Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
US20120225129A1 (en) 2010-08-20 2012-09-06 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
US9999673B2 (en) 2011-01-11 2018-06-19 Alnylam Pharmaceuticals, Inc. PEGylated lipids and their use for drug delivery
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
KR20220025112A (en) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Lipid nanoparticle compositions and methods for mrna delivery
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
JP6250543B2 (en) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド Dialiphatic substituted PEGylated lipids
US8762704B2 (en) 2011-09-29 2014-06-24 Apple Inc. Customized content for electronic devices
CA2853689C (en) 2011-11-04 2020-06-30 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
DE21212055T1 (en) 2011-12-07 2022-08-04 Alnylam Pharmaceuticals, Inc. BIODEGRADABLE LIPIDS TO RELEASE ACTIVE INGREDIENTS
WO2013086322A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
ES2923757T3 (en) 2011-12-16 2022-09-30 Modernatx Inc Modified mRNA compositions
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
US9415109B2 (en) 2012-07-06 2016-08-16 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
WO2015011633A1 (en) * 2013-07-23 2015-01-29 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
CA2953341C (en) * 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
HUE067372T2 (en) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017070624A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
CN108368028B (en) 2015-10-28 2021-09-03 爱康泰生治疗公司 Novel lipid and lipid nanoparticle formulations for delivery of nucleic acids
WO2018081480A1 (en) * 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
KR20190093816A (en) 2016-10-26 2019-08-26 큐어백 아게 Lipid nanoparticle mRNA vaccine
US20180185516A1 (en) * 2016-12-09 2018-07-05 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
US11820728B2 (en) 2017-04-28 2023-11-21 Acuitas Therapeutics, Inc. Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3688162B1 (en) * 2017-09-29 2024-03-06 Intellia Therapeutics, Inc. Formulations
MA50522B1 (en) 2017-10-31 2022-09-30 Astrazeneca Ab 151 85 Soedertaelje Lipid nanoparticles for delivery of a modified rna encoding a vegf-a polypeptide
WO2019089828A1 (en) * 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP3852911B1 (en) 2018-09-21 2025-01-22 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
PL3908568T3 (en) 2019-01-11 2024-12-02 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents

Also Published As

Publication number Publication date
AU2026203397A1 (en) 2026-05-21
GB2600859A (en) 2022-05-11
DOP2022000038A (en) 2023-01-31
UA129330C2 (en) 2025-03-19
PL4013385T3 (en) 2024-11-18
ES2918001B2 (en) 2026-05-13
AU2020328596A1 (en) 2022-03-31
EP4013385B1 (en) 2024-07-03
JOP20220037A1 (en) 2023-01-30
JP7753190B2 (en) 2025-10-14
JP2022544652A (en) 2022-10-20
JP2025173509A (en) 2025-11-27
FI4013385T3 (en) 2024-09-27
ES2918001R1 (en) 2025-02-18
DK4013385T3 (en) 2024-09-02
SI4013385T1 (en) 2024-10-30
CL2022000351A1 (en) 2023-02-03
WO2021030701A1 (en) 2021-02-18
ES2992930T3 (en) 2024-12-19
IL290477A (en) 2022-04-01
CO2022002685A2 (en) 2022-04-19
MX2022001720A (en) 2022-03-11
PH12022550363A1 (en) 2023-02-27
PT4013385T (en) 2024-10-01
CN114901253A (en) 2022-08-12
EP4454640A2 (en) 2024-10-30
BR112022002708A2 (en) 2022-05-31
GB2600859B (en) 2024-04-03
HUE068356T2 (en) 2024-12-28
KR20220053599A (en) 2022-04-29
EP4454640A3 (en) 2025-02-12
LT4013385T (en) 2024-09-25
US20230097090A1 (en) 2023-03-30
CR20220108A (en) 2022-05-27
PE20220968A1 (en) 2022-06-10
EP4013385A1 (en) 2022-06-22
GEP20257820B (en) 2025-11-10
DE112020003843T5 (en) 2022-05-19
ES2918001A2 (en) 2022-07-13
MX2025003983A (en) 2025-05-02
CA3150458A1 (en) 2021-02-18
GEAP202515904A (en) 2025-07-10
AU2020328596B2 (en) 2026-02-12
HRP20241255T1 (en) 2024-12-06

Similar Documents

Publication Publication Date Title
CR20220108A (en) ENHANCED LIPID NANOPARTICLES FOR THE DELIVERY OF NUCLEIC ACIDS
GT201700056A (en) USE OF LONG-ACTING GLP-1 / GLUCAGON RECEPTOR DUAL AGONIST FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE.
CY1122899T1 (en) AQUEOUS FORMULATION INCLUDING PARACETAMOL AND IBUPROPHEN
MX2018001723A (en) Multi-ligand drug conjugates and uses thereof.
MX379286B (en) PCSK9 INHIBITORS FOR USE IN THE TREATMENT OF PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH).
MA39443A1 (en) New meloxicam formulation
PH12020500076A1 (en) Long-acting formulations
PE20181332A1 (en) METHODS OF SEDATION AND PARENTERAL FORMULATION FOR USE DURING THE TREATMENT OF CRITICAL CARE
DOP2016000254A (en) PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE.
ECSP14023048A (en) OPTIMIZED THERAPEUTIC AGENTS FOR SUBCUTANEOUS ADMINISTRATION
CO2019004776A2 (en) New quinoline-3-carboxamide derivatives anthelmintics
MX2016015437A (en) COMBINATION THAT INCLUDES A GLUCOCORTICOID AND EDO-S101.
MX2018008903A (en) COMPOSITIONS AND METHODS OF USE OF ß-HIDROXI-ß-METHYLBUTIRATE (HMB) TO MODULATE AUTOFAGIA AND LIPOFAGIA.
AR111374A1 (en) USE OF LIK066 IN PATIENTS WITH HEART FAILURE
AR073089A1 (en) DERIVATIVES OF (POLI) AMINOALQUILAMINOALQUILAMIDAS, ALQUIL-UREA OR ALQUILSULFONAMIDA OF EPIPODOFILOTOXINA, A PROCESS TO PREPARE THEM, ITS APPLICATION IN THERAPY AS ANTICANCER AGENTS AND PHARMACEUTICAL COMPOSITION THAT CONTAIN THEM.
CL2021000627A1 (en) Pharmaceutical compositions suitable for joint release and their use in the treatment of joint pain
CL2019003288A1 (en) A pharmaceutical combination for the treatment of cancer.
CL2017000971A1 (en) Pharmaceutical composition for use in increasing trophism of nasal mucosa
BR112018007399A2 (en) composition, method of treatment, part kit and dosage form
BR112019017314A2 (en) pharmaceutical compositions for combination therapy
CL2017001941A1 (en) Use of a mixture of modified glucose polymers to reduce tumor metastases
CO6491023A2 (en) USE OF THE COMBINATION OF TERIFLUNOMIDE AND INTERFERON BETA FOR THE TREATMENT OF MULTIPLE SCLEROSIS
BR112018002970A2 (en) etanercept's improved stability composition
AR103448A1 (en) INTESTINAL GEL OF LEVODOPA AND CARBIDOPA AND METHODS OF USE
PE20151665A1 (en) ORAL ANTISEPTIC COMPOSITION FOR THE TREATMENT OF ORAL MUCOSITIS